SRZN

SEC source: 0001593968-25-000043 · primary_01.xml · nonDerivative · entry 2

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,345

F3 · price: The shares were sold to cover withholding taxes upon vesting of RSUs in transactions that were initiated by the Issuer on the reporting person's behalf. The price reported reflects the volume-weighted average price for the transactions.

SEC source: 0001593968-25-000041 · primary_01.xml · nonDerivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,163

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock. This transaction represents the settlement of vested RSUs in shares of the Issuer's common stock.

F2 · balance_after: Includes 400 shares purchased at a price of $5.67 per share pursuant to the Issuer's 2021 Employee Stock Purchase Plan on December 13, 2024.

SEC source: 0001593968-25-000043 · primary_01.xml · nonDerivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,188

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock. This transaction represents the settlement of vested RSUs in shares of Issuer's common stock.

F2 · balance_after: Includes 400 shares purchased at a price of $5.67 per share pursuant to the Issuer's 2021 Employee Stock Purchase Plan on December 13, 2024, and 702 shares held through immediate family members of the reporting person.

SEC source: 0001593968-24-000868 · primary_01.xml · nonDerivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,863

F1 · kind: This reporting person is voluntarily reporting these shares acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-24-000867 · primary_01.xml · nonDerivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,824

F1 · kind: This reporting person is voluntarily reporting these shares acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-24-000869 · primary_01.xml · nonDerivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,888

F1 · kind: This reporting person is voluntarily reporting these shares acquired under the Surrozen, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).

SEC source: 0001593968-24-000826 · primary_01.xml · derivative · entry 1

Berkenblit Anna · CIK 0001691868 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000834 · primary_01.xml · derivative · entry 1

WOODHOUSE DAVID J · CIK 0001642995 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000828 · primary_01.xml · derivative · entry 1

CHAI CHRISTOPHER Y · CIK 0001413823 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000827 · primary_01.xml · derivative · entry 1

BJERKHOLT ERIC · CIK 0001197350 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000831 · primary_01.xml · derivative · entry 1

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000833 · primary_01.xml · derivative · entry 1

Lin Shao-Lee · CIK 0001725092 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000832 · primary_01.xml · derivative · entry 1

Rothenberg Mace · CIK 0001873988 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000830 · primary_01.xml · derivative · entry 1

Haak-Frendscho Mary · CIK 0001873902 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,333

Underlying: Common Stock · 1,333 shares

Expires 2034-06-05

F1 · derivative.exercise_date: The options vest and become exercisable on the anniversary of the grant date, subject to continuous service as a director.

SEC source: 0001593968-24-000679 · primary_01.xml · derivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2034-05-01

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on June 1, 2024, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-24-000678 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,000

Underlying: Common Stock · 43,000 shares

Expires 2034-05-01

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on June 1, 2024, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-24-000680 · primary_01.xml · derivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2034-05-01

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on June 1, 2024, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-24-000620 · primary_01.xml · derivative · entry 2

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,000

Underlying: Common Stock · 7,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSU award vests in two equal installments on January 1, 2025 and January 1, 2026.

F3 · derivative.expiration_date: The RSU award vests in two equal installments on January 1, 2025 and January 1, 2026.

SEC source: 0001593968-24-000620 · primary_01.xml · derivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 13,000 shares

Expires 2034-04-24

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on February 1, 2024, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-24-000621 · primary_01.xml · derivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,000

Underlying: Common Stock · 43,000 shares

Expires 2034-04-24

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on February 1, 2024, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0001593968-24-000622 · primary_01.xml · derivative · entry 2

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires not disclosed

F2 · derivative.exercise_price: Each restricted stock unit, or RSU, represents a contingent right to receive one share of the Issuer's common stock.

F3 · derivative.exercise_date: The RSU award vests in two equal installments on January 1, 2025 and January 1, 2026.

F3 · derivative.expiration_date: The RSU award vests in two equal installments on January 1, 2025 and January 1, 2026.

SEC source: 0001593968-24-000622 · primary_01.xml · derivative · entry 1

Li Yang · CIK 0001990537 · Exec. Vice President, Research

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,000

Underlying: Common Stock · 10,000 shares

Expires 2034-04-24

F1 · derivative.exercise_date: The shares subject to the options vest and become exercisable in a series of 48 equal monthly installments beginning on February 1, 2024, subject to the reporting person's continuous service through the applicable vesting date.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 10

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 397,773

Underlying: Common Stock · 397,773 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F7 · derivative.exercise_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F7 · derivative.expiration_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 9

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 352,225

Underlying: Common Stock · 352,225 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F7 · derivative.exercise_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F7 · derivative.expiration_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 8

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 397,773

Underlying: Common Stock · 397,773 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F6 · derivative.exercise_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F6 · derivative.expiration_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 7

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 352,225

Underlying: Common Stock · 352,225 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F6 · derivative.exercise_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F6 · derivative.expiration_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 6

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 111,656

Underlying: Common Stock · 111,656 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F5 · derivative.exercise_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F5 · derivative.expiration_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 5

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 98,870

Underlying: Common Stock · 98,870 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F5 · derivative.exercise_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F5 · derivative.expiration_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 4

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 102,651

Underlying: Common Stock · 102,651 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F4 · derivative.exercise_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F4 · derivative.expiration_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · derivative · entry 3

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 90,897

Underlying: Common Stock · 90,897 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F4 · derivative.exercise_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F4 · derivative.expiration_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 332,885

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042633 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner

COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner

COLUMN GROUP III, LP · CIK 0001668159 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 294,767

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0001593968-24-000563 · primary_01.xml · derivative · entry 5

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,712

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F4 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

F4 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

SEC source: 0001593968-24-000563 · primary_01.xml · derivative · entry 4

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,712

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F3 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

F3 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

SEC source: 0001593968-24-000563 · primary_01.xml · derivative · entry 3

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,603

Underlying: Common Stock · 1,603 shares

Expires not disclosed

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F2 · derivative.expiration_date: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

SEC source: 0001593968-24-000563 · primary_01.xml · derivative · entry 2

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,474

Underlying: Common Stock · 1,474 shares

Expires 2029-04-04

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

SEC source: 0001593968-24-000563 · primary_01.xml · nonDerivative · entry 1

Williams Charles O · CIK 0001325818 · CFO and COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,474

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

SEC source: 0001593968-24-000562 · primary_01.xml · derivative · entry 5

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,712

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F4 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

F4 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series D Milestone Event (as defined in the Series D Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series D Common Stock Warrant).

SEC source: 0001593968-24-000562 · primary_01.xml · derivative · entry 4

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,712

Underlying: Common Stock · 5,712 shares

Expires not disclosed

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F3 · derivative.exercise_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

F3 · derivative.expiration_date: The warrant is exercisable for 30 days after the earlier of (i) the occurrence of the Series C Milestone Event (as defined in the Series C Common Stock Warrant) and (ii) a Fundamental Transaction (as defined in the Series C Common Stock Warrant).

SEC source: 0001593968-24-000562 · primary_01.xml · derivative · entry 3

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,603

Underlying: Common Stock · 1,603 shares

Expires not disclosed

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

F2 · derivative.expiration_date: The warrant expires on the fifth trading day following the occurrence of the Series B Milestone Event (as defined in the Series B Common Stock Warrant). In the event the Series B Milestone Event has not occurred prior to the fifth anniversary of the issuance date of the warrant, the warrant will automatically terminate on such anniversary date.

SEC source: 0001593968-24-000562 · primary_01.xml · derivative · entry 2

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,474

Underlying: Common Stock · 1,474 shares

Expires 2029-04-04

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

SEC source: 0001593968-24-000562 · primary_01.xml · nonDerivative · entry 1

Parker Craig C · CIK 0001526064 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,474

F1 · price: On April 4, 2024, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of April 1, 2024, by and among the Issuer and certain institutional investors and members of management, at a purchase price of $16.96 per share, which amount includes $1.25 for the accompanying common stock warrants.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 10

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 397,773

Underlying: Common Stock · 397,773 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F7 · derivative.exercise_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F7 · derivative.expiration_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 9

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 352,225

Underlying: Common Stock · 352,225 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F7 · derivative.exercise_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F7 · derivative.expiration_date: These Series D Common Warrants are exercisable for 30 days following the Issuer's announcement of the enrollment of at least 50 patients in the SZN-043 Phase 2/3 clinical trial for the treatment of severe alcohol-associated hepatitis. The Series D Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series D Warrants).

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 8

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 397,773

Underlying: Common Stock · 397,773 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F6 · derivative.exercise_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F6 · derivative.expiration_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 7

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 352,225

Underlying: Common Stock · 352,225 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F6 · derivative.exercise_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F6 · derivative.expiration_date: These Series C Common Warrants are exercisable for 30 days following the Issuer's announcement of final data from the SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis. The Series C Common Warrants will also become exercisable in the event of a Fundamental Transaction (as defined in the Series C Warrants).

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 6

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 111,656

Underlying: Common Stock · 111,656 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F5 · derivative.exercise_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F5 · derivative.expiration_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 5

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 98,870

Underlying: Common Stock · 98,870 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F5 · derivative.exercise_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F5 · derivative.expiration_date: These Series B Common Warrants are exercisable immediately upon issuance and expire on the fifth trading day following the Issuer's announcement that (i) it has completed the enrollment of at least 15 patients with a 30-day mortality rate less than 30% in the Issuer's SZN-043 Phase 1b clinical trial for the treatment of severe alcohol-associated hepatitis, with no recommended changes by the Safety Review Committee to the study design, including changes related to dose or schedule, and (ii) Safety Review Committee approval for the Issuer to advance to a higher dose cohort.

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 4

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III-A, LP

Disclosed balance after: 102,651

Underlying: Common Stock · 102,651 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F4 · derivative.exercise_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F4 · derivative.expiration_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F3 · ownership.nature: The securities are directly held by TCG III-A LP. TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the Managing Partners. The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

SEC source: 0000950170-24-042636 · ownership.xml · derivative · entry 3

Kutzkey Tim · CIK 0001614186 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · By The Column Group III, LP

Disclosed balance after: 90,897

Underlying: Common Stock · 90,897 shares

Expires not disclosed

F1 · price: Represents a price per unit, consisting of (i) $14.25 per share of the Issuer's Common Stock and (ii) $1.25 attributable to accompanying warrants to purchase shares of the Issuer's Common Stock, which The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP") purchased in the Issuer's private placement on April 4, 2024.

F4 · derivative.exercise_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F4 · derivative.expiration_date: These Series A Common Warrants are immediately exercisable and expire on April 4, 2029.

F2 · ownership.nature: The securities are directly held by TCG III LP. The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and the Reporting Person, a member of the Issuer's board of directors (collectively, the "Managing Partners"). The Managing Partners may be deemed to share voting and investment power with respect to such securities. TCG III GP and each of the Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.